CCDC6 coiled-coil domain containing 6
ENSG00000108091 · protein coding · Open Targets profile
Acts as a structural scaffold that organizes free PP2Ac into a configuration that FBXO42 can recognize and ubiquitinate, leading to its proteasomal degradation (PubMed:41986709). Also interacts independently with PPP4C through a mechanism distinct from FBXO42- mediated ubiquitination (PubMed:41484364). .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, High-Quality Ligand
- PROTAC
- Database Ubiquitination, Half-life Data, Small Molecule Binder
gnomAD loss of function constraint: o/e 0.3535099923610687 (upper bound 0.5136799812316895). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 37 registry trials, updated in the last three years, of the most advanced drugs against CCDC6 (selpercatinib), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Yasir Y ElaminSWOG Cancer Research Network · 2 of 2 trials Phase 2+
- Andrea T FransonChildren's Oncology Group · 1 of 1 trials Phase 2+
- Åslaug HellandOslo University Hospital · 1 of 1 trials Phase 2+
- Donald W ParsonsChildren's Oncology Group · 1 of 1 trials Phase 2+
- Dongmei JiFudan University · 1 of 1 trials Phase 2+
- E.E. VoestThe Netherlands Cancer Institute · 1 of 1 trials Phase 2+
- Helena A YuMemorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA · 1 of 1 trials Phase 2+
- Inna Markovna ChenHerlev Sygehus · 1 of 1 trials Phase 2+
- Lori J. WirthMassachusetts General Hospital · 1 of 1 trials Phase 2+
- Mark ZafereoM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Qinghai JiFudan University · 1 of 1 trials Phase 2+
- Theodore LaetschChildren's Hospital of Philadelphia · 1 of 1 trials Phase 2+
- Yansong LinPeking Union Medical College Hospital · 1 of 1 trials Phase 2+
- Yu WangFudan University · 1 of 1 trials Phase 2+
- Nirmal ChoradiaUniversity of Oklahoma - Stephenson Cancer Center · 0 of 1 trials Phase 2+
Registry trials of selpercatinib updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 28 of 36 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 1 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
1 trials of drugs against CCDC6 were stopped early
Terminated, withdrawn and suspended interventional trials of selpercatinib, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 1 most recent of 1.
- withdrawn · 2024-07-09 · SWOG Cancer Research Network · Selpercatinib“lack of accrual”
Paediatric incentives and obligations for CCDC6's drugs
For selpercatinib: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · CCDC6 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-002544-PIP01-18-M02 (selpercatinib, Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)): PM: decision on the application for modification of an agreed PIP, 13 Apr 2023Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMEA-002544-PIP01-18-M02, 2026-11-11
- EU orphan designation: no · No EU orphan designation names selpercatinibRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Retsevmo: authorised since 11 Feb 2021Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Retsevmo, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: yes · Selpercatinib [Retevmo], 29 May 2024: Treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options; Selpercatinib [Retevmo], 29 May 2024: Treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate); Selpercatinib [Retevmo], 29 May 2024: Treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapyRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 12 interventional studies of selpercatinib include patients under 18; 11 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 2 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.